Stay updated with breaking news from Acelyrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Acelyrin Inc opened 28% above offering price in their market debut on Friday, giving the biopharma company a market capitalization of $2.1 billion. The Los Angeles-based... | May 5, 2023
Following is a summary of current health news briefs. US FDA declines to approve Ascendis' hormone disorder therapy Ascendis Pharma A/S said on Monday the U.S. Food & Drug Administration had declined to approve the Danish drugmaker's experimental therapy to treat adult patients with a hormone disorder called hypoparathyroidism, citing concerns linked to manufacturing control of the drug and device combination.
Biotech IPOs continues to be almost non-existent, but Acelyrin wants to see if the public markets have an appetite for its lead drug candidate. The small protein drug could match up favorably against blockbuster biologics and it has reached pivotal testing in three inflammatory disorders.
/PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...
/PRNewswire/ -- ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in...